Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/14242

Registo completo
Campo DCValorIdioma
dc.contributor.authorBalmayor, Elizabeth Rosado-
dc.contributor.authorAzevedo, Helena S.-
dc.contributor.authorReis, R. L.-
dc.date.accessioned2011-11-10T15:08:50Z-
dc.date.available2011-11-10T15:08:50Z-
dc.date.issued2011-06-
dc.identifier.issn0724-8741por
dc.identifier.issn1573-904Xpor
dc.identifier.urihttps://hdl.handle.net/1822/14242-
dc.description.abstractDuring the last few decades, a fair amount of scientific investigation has focused on developing novel and efficient drug delivery systems. According to different clinical needs, specific biopharmaceutical carriers have been proposed. Micro-and nanoparticulated systems, membranes and films, gels and even microelectronic chips have been successfully applied in order to deliver biopharmaceuticals via different anatomical routes. The ultimate goal is to deliver the potential drugs to target tissues, where regeneration or therapies (chemotherapy, antibiotics, and analgesics) are needed. Thereby, the bioactive molecule should be protected against environmental degradation. Delivery should be achieved in a dose-and time-correct manner. Drug delivery systems (DDS) have been conceived to provide improvements in drug administration such as ability to enhance the stability, absorption and therapeutic concentration of the molecules in combination with a long-term and controlled release of the drug. Moreover, the adverse effects related with some drugs can be reduced, and patient compliance could be improved. Recent advances in biotechnology, pharmaceutical sciences, molecular biology, polymer chemistry and nanotechnology are now opening up exciting possibilities in the field of DDS. However, it is also recognized that there are several key obstacles to overcome in bringing such approaches into routine clinical use. This review describes the present state-of-the-art DDS, with examples of current clinical applications, and the promises and challenges for the future in this innovative field.por
dc.description.sponsorshipThis work was supported through the European Union funded projects Marie Curie Host Fellowships for Early Stage Research Training (EST) "Alca Jacta EST" (MEST-CT-2004-008104), which provided E. R. Balmayor with a PhD fellowship, and the European Network of Excellence EXPERTISSUES (NMP3-CT-2004-500283).por
dc.language.isoengpor
dc.publisherSpringerpor
dc.rightsrestrictedAccesspor
dc.subjectCell encapsulationpor
dc.subjectDDS routes of administrationpor
dc.subjectGene therapypor
dc.subjectGrowth factorspor
dc.subjectNanotechnologypor
dc.subjectRegenerative medicinepor
dc.titleControlled delivery systems: from pharmaceuticals to cells and genespor
dc.typearticle-
dc.peerreviewedyespor
sdum.publicationstatuspublishedpor
oaire.citationStartPage1241por
oaire.citationEndPage1258por
oaire.citationIssue6por
oaire.citationTitlePharmaceutical Researchpor
oaire.citationVolume28por
dc.identifier.doi10.1007/s11095-011-0392-ypor
dc.identifier.pmid21424163por
dc.subject.wosScience & Technologypor
sdum.journalPharmaceutical Researchpor
Aparece nas coleções:3B’s - Artigos em revistas/Papers in scientific journals

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
ERBalmayorControlledDeliverySystems_PharmRes2011.pdf
Acesso restrito!
Main article1,05 MBAdobe PDFVer/Abrir

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID